inVentiv Health Executives Named to PharmaVOICE 100 List of Most Inspiring Leaders
Kim Johnson, Mike Menta and Jeanine O’Kane Honored by Colleagues and Clients in the Life Sciences Industry for Leadership in Drug Commercialization
BURLINGTON, Mass. – August 5, 2015 – inVentiv Health, a top-tier professional services organization that accelerates the clinical and commercial success of biopharmaceutical companies worldwide, announced today that three of its senior executives have been named to the prestigious PharmaVOICE 100 list of the most inspiring leaders in the life sciences industry.
The three winners include Kim Johnson, President of PALIO; Mike Menta, Chief Operating Officer of Campbell Alliance; and Jeanine O’Kane, Managing Director of Biosector 2. Based on thousands of colleague and client submitted nominations, the awards span various areas of expertise from marketing to research and development, acknowledging individuals making positive impacts on their businesses, communities and the world of healthcare.
“We congratulate our honorees, who are tackling some of the most critical drug commercialization issues facing the industry,” said Michael Griffith, Executive Vice President, inVentiv Health and President, inVentiv Health Commercial Division. “Their drive to accelerate client success and facilitate the delivery of medicines to those who need them most is an inspiration to us all.”
The inVentiv Health winners lead and mentor global teams who create faster processes, better practices and smarter systems to deliver exceptional client results. Their work spans decades and includes expertise in a broad set of drug commercialization activities, including advertising, public relations, public affairs and consulting, as described in the current edition of PharmaVOICE magazine:
- Kim Johnson, PALIO: As the first woman president of PALIO, an inVentiv Health advertising agency known for creating compelling healthcare brand narratives, Johnson has ignited a new wave of thinking at the agency since she joined the organization in 2014. Her roadmap for the agency centers on four strategic imperatives: brilliant ideas, strategic excellence, transformative technology and community cultivation. Under her vision, PALIO has built a diverse book of domestic and global business – ranging from traditional and digital agency of record partnerships across pharmaceutical, medical technology and wellness brands. PALIO’s full service advertising offering focuses on strategic and creative development, customer engagement and analytics.
- Mike Menta, Campbell Alliance: Menta, Chief Operating Officer of Campbell Alliance is known as a true partner to biopharmaceutical companies. From his role at inVentiv Health’s consulting firm, he addresses some of the industry’s toughest challenges with a level of sophistication and savvy that is unparalleled. Menta’s ability to break down complex problems into component parts and then craft creative, compelling solutions has been recognized and appreciated by clients and members of the consulting team alike. Menta’s strategic foresight and ability to identify emerging industry needs allowed him to steer one of Campbell’s smaller practice areas and dramatically expand it.
- Jeanine O’Kane, Biosector 2: PharmaVOICE recognizes O’Kane, Managing Director of Biosector 2, for being a passionate and fearless leader who delivers innovative solutions. She has continued to build Biosector 2, an inVentiv Health PR Group company, into a best-in-class communications agency servicing the health industry, even during the uncertainties of the patent cliff era and the implementation of the Affordable Care Act. Under O'Kane's management, the agency has won PRWeek’s Healthcare Campaign of the Year and been named The Holmes Report's Best Healthcare Consultancy in the World, among a myriad of other industry awards.
"As brave thinkers and passionate industry experts, these are the people helping our clients navigate through an ever-changing biopharmaceutical landscape," said Griffith. "We are proud of the roles these individuals play within the organization, serving as role models, collaborators and leaders."
PharmaVOICE is expressly written and designed to deliver the views, opinions and insights of executives who are shaping the direction of the dynamic life-sciences industry. PharmaVOICE’s multiple-perspective and in-depth original forums, feature articles, topics and departments are audience-driven. PharmaVOICE provides executives with useful peer-to-peer insights on a broad range of business practices and topics to a wide range of life-science sectors.
About inVentiv Health
inVentiv Health is a top-tier professional services organization that accelerates the clinical and commercial success of biopharmaceutical companies worldwide. Our combined Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) help clients improve their performance to deliver much-needed therapies to market. With 13,000 employees providing services to clients in 70 countries, inVentiv Health designs best practices, processes and systems to enable clients to successfully navigate an increasingly complex environment. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv Health management team.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays, cancellations and terminations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of any future acquisitions; the impact of any change in our current credit ratings or the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our debt instruments and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operations, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our clients; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; the impact of impairment of goodwill and intangible assets and the factors leading to such impairments; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.